Zymiq Technology (ZYMIQ) Q2 2026 earnings summary

Executive summary

• Focused on preparations for a planned listing on Nasdaq First North Growth Market, including renegotiation of key agreements, balance sheet measures, and financing preparations.

• Marketing plans for Kalzyme and DentaPrev continued, with the foundation laid for the next growth phase.

• CEO highlights strategic decisions, balance sheet cleaning, and bridge financing to support growth and commercialization.

Financial highlights

• Q2 2026 net sales: SEK 13 thousand (Q2 2025: SEK 334 thousand); H1 2026 net sales: SEK 848 thousand (H1 2025: SEK 1,146 thousand).

• Q2 2026 loss after tax: SEK -5,477 thousand (Q2 2025: SEK -3,149 thousand); H1 2026 loss after tax: SEK -9,103 thousand (H1 2025: SEK -5,212 thousand).

• Q2 2026 earnings per share: SEK -0.58 (Q2 2025: SEK -0.37); H1 2026 EPS: SEK -0.98 (H1 2025: SEK -0.61).

• Cash and cash equivalents at period end: SEK 1,010 thousand (Q2 2025: SEK 888 thousand).

• Equity at period end: SEK 15,144 thousand (Q2 2025: SEK 19,090 thousand); equity-asset ratio: 59% (Q2 2025: 81%).

Outlook and guidance

• Listing on Nasdaq First North Growth Market expected after Q3 2026.

• Continued investment in growth areas, with focus on commercialization and scaling of Kalzyme and DentaPrev.

• Aggressive timetable for DentaPrev tablet launch before Christmas, leveraging digital channels.